ATAD3A Patient Advocacy Alliance Revenue

Hospitals and Health Care • Fort Collins, Colorado, United States • 1-10 Employees

ATAD3A Patient Advocacy Alliance revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Hospitals and Health Care industry and current estimated revenues	$821,328
Total funding	No funding

Key Contact at ATAD3A Patient Advocacy Alliance

Erika Benti

President

Company overview

Headquarters	Fort Collins, Colorado, United States
NAICS	923
Keywords	Biorepository, Gene Therapy, Promoting, Families, Research, Support, Biobanking, Funding, Empower, Patients, Pediatric Neurology, Advocate, Medical Care, Patient Advocacy, Raise Awareness, Global Collaboration, Mitochondrial Dysfunction, Data Sharing, Caregivers, Rare Disease, Clinicians, Researchers, Mitochondrial Diseases, Rare Disease Awareness, Improving Lives, Rare Genetic Disorders, Clinical Trial Engagement, Atad3A, Data And Tissue Samples, Enhance Treatment, Gene-Relates Disorders, Genetic Research Collaboration, Harel-Yoon Syndrome, Patient-Derived Tissue Samples, Patient-Led Research Initiatives, Rare Disease Foundations, Tissue Bank Access, Ultra-Rare Disease
Founded	2025
Employees	1-10

About ATAD3A Patient Advocacy Alliance

The ATAD3A Patient Advocacy Alliance is committed to improving the lives of individuals affected by ATAD3A gene-related disorders, including Harel-Yoon syndrome. We support groundbreaking scientific research, provide information and a support network for patients and families, and advocate for improved medical care. Through global collaboration with researchers, clinicians, and industry leaders, we strive to accelerate discoveries, enhance treatment options, and drive meaningful change for those affected. ABOUT ATAD3A: Mutations of the ATAD3A gene are also called Harel-Yoon Syndrome. These mutations can be inherited from the patients' parents or occur spontaneously during gene replication (de novo) in the patient. ATAD3A mutations are rare, with less than 100 confirmed cases worldwide. Symptoms of this neurodevelopmental disorder vary by patient, but may include developmental delay, intellectual disability, mitochondrial disorder, hypotonia, feeding difficulty and issues with the eyes and heart, among others. This syndrome is considered progressive, meaning that symptoms tend to worsen over time. Website coming soon.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Vice President

Funding Data

ATAD3A Patient Advocacy Alliance has never raised funding before.

Frequently asked questions

ATAD3A Patient Advocacy Alliance is located in Fort Collins, Colorado, US.

ATAD3A Patient Advocacy Alliance generates an estimated annual revenue of $256,665. This revenue figure reflects the company's market position and business performance in its industry.

ATAD3A Patient Advocacy Alliance has an estimated valuation of $821,328. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

ATAD3A Patient Advocacy Alliance was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.

ATAD3A Patient Advocacy Alliance has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at ATAD3A Patient Advocacy Alliance

Erika Benti

President

4.8

40,000 users